NCT06764680View on ClinicalTrials.gov

Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Colorectal Cancer MetastaticChemotherapyTargeted TherapyImmunotherapyRadiotherapy, Intensity-Modulated
Interventions
DRUG

Trifluorouracil tepidopyrimidine

30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w

DRUG

Bevacizumab

5mg/kg. ivgtt. d1 and d15. q4w

DRUG

Sindilizumab

200mg. ivgtt. d1. q4w

RADIATION

IMRT

In terms of obstruction, bleeding, compression, or pain due to a tumor that requires local treatment. IMRT was delivered to the involved lesions.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER